Conversion Labs: Telehealth Subscriptions

By -

 

  • Conversion Labs was highlighted in a bull call by Citron Research.
  • The company is building a DTC health and wellness platform focused on subscription services.
  • Q4 revenues surged 265% to $13.6 million.
  • The stock is cheap compared to other telehealth brands trading at less than 5x EV/S multiples.
  • This idea was discussed in more depth with members of my private investing community, Out Fox The Street. Get started today »

The telehealth space was hot in 2020 and Conversion Labs (CVLB) is playing perfectly into this trend. The company is quickly ramping up some new direct-to-consumer subscription services while building a telehealth platform for future products. The stock is appealing here after a notable firm made a bullish case on the stock.

Read the full article on Seeking Alpha. 


Disclosure: No positioned mentioned. Please review the disclaimer page for more details. 

Comments

Post a Comment

Popular posts from this blog

Camping World: Momentum Stinks

By -
Image
1/2/19 Update  Camping World announced a major reorg including the hiring of a new CFO. The sudden resignation of the President of RV Operations looks more and more like a personal decision due to a disagreement with the organizational shifts and his new place in the business. The stock is up about 5% to $12. Considering these reorgs usually occur when business is struggling, the recommendation isn't to jump into the stock on the rip. Continue to use dips to buy Camping World for the long term as 2019 could be another rough year. Original Article   The last thing a weak stock needs is an executive departure. Camping World (CWH) is crashing to new lows based on the surprise resignation of the President of RV Operations. One of the reasons to invest in Camping World was the solid management team lead by CEO Marcus Lemonis and other executives like Roger Nuttall with decades of experience in the industry. Naturally, the market is worried by a surprise move on a Friday even
Read more

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more